
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
The company recalls products due to sterility concerns.
FDA announced on May 17, 2016 that Well Care Compounding Pharmacy (Las Vegas, NV) is voluntarily recalling sterile compounded products distributed between Jan. 1–April 29, 2016. The recall comes after an FDA inspection of the facility that resulted in sterility assurance concerns.
The company states in a
Source:






